Stay updated on DSP-5336 in Relapsed AML Clinical Trial
Sign up to get notified when there's something new on the DSP-5336 in Relapsed AML Clinical Trial page.

Latest updates to the DSP-5336 in Relapsed AML Clinical Trial page
- Check3 days agoChange DetectedRevision tag updated from v3.5.3 to v3.5.4, indicating a page-level update. This change signals a deployment or refresh of the page without altering the study details or visible fields.SummaryDifference0.0%

- Check10 days agoNo Change Detected
- Check17 days agoNo Change Detected
- Check25 days agoChange DetectedThe page footer revision/version indicator was updated from **v3.5.2** to **v3.5.3**.SummaryDifference0.0%

- Check32 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check53 days agoChange Detected- Added Horizon-1 Phase 1/2 study of Enzomenib (DSP-5336) in acute leukemia with multiple arms, SOC combinations, and a detailed global site list. Replaced the former DSP-5336 relapsed/refractory AML/ALL study description with the Horizon-1 protocol and expanded indications and design.SummaryDifference8%

- Check61 days agoChange DetectedRevision indicator updated to v3.5.0. The previous revision v3.4.3 was removed.SummaryDifference0.0%

- Check75 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3; no visible content changes.SummaryDifference0.0%

Stay in the know with updates to DSP-5336 in Relapsed AML Clinical Trial
Enter your email address, and we'll notify you when there's something new on the DSP-5336 in Relapsed AML Clinical Trial page.